These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 22950865)

  • 21. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid biomarkers mirror rate of cognitive decline.
    Rolstad S; Berg AI; Bjerke M; Johansson B; Zetterberg H; Wallin A
    J Alzheimers Dis; 2013; 34(4):949-56. PubMed ID: 23313924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years.
    Stomrud E; Hansson O; Minthon L; Blennow K; Rosén I; Londos E
    Neurobiol Aging; 2010 Feb; 31(2):215-23. PubMed ID: 18462837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.
    Pettigrew C; Soldan A; Sloane K; Cai Q; Wang J; Wang MC; Moghekar A; Miller MI; Albert M;
    Neuroimage Clin; 2017; 16():439-446. PubMed ID: 28879085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Processing resources reduce the effect of Alzheimer pathology on other cognitive systems.
    Boyle PA; Wilson RS; Schneider JA; Bienias JL; Bennett DA
    Neurology; 2008 Apr; 70(17):1534-42. PubMed ID: 18354077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.
    Ingber AP; Hassenstab J; Fagan AM; Benzinger TL; Grant EA; Holtzman DM; Morris JC; Roe CM
    J Alzheimers Dis; 2016; 52(3):1055-64. PubMed ID: 27104893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia.
    Eckerström C; Olsson E; Bjerke M; Malmgren H; Edman A; Wallin A; Nordlund A
    J Alzheimers Dis; 2013; 36(3):421-31. PubMed ID: 23635408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia.
    Oikonomidi A; Tautvydaitė D; Gholamrezaee MM; Henry H; Bacher M; Popp J
    J Alzheimers Dis; 2017; 60(1):273-281. PubMed ID: 28826184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple category verbal fluency in mild cognitive impairment and correlation with CSF biomarkers for Alzheimer's disease.
    Mirandez RM; Aprahamian I; Talib LL; Forlenza OV; Radanovic M
    Int Psychogeriatr; 2017 Jun; 29(6):949-958. PubMed ID: 28179036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSF biomarkers and clinical progression of Parkinson disease.
    Hall S; Surova Y; Öhrfelt A; Zetterberg H; Lindqvist D; Hansson O
    Neurology; 2015 Jan; 84(1):57-63. PubMed ID: 25411441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.
    van Waalwijk van Doorn LJ; Gispert JD; Kuiperij HB; Claassen JA; Arighi A; Baldeiras I; Blennow K; Bozzali M; Castelo-Branco M; Cavedo E; Emek-Savaş DD; Eren E; Eusebi P; Farotti L; Fenoglio C; Ormaechea JF; Freund-Levi Y; Frisoni GB; Galimberti D; Genc S; Greco V; Hampel H; Herukka SK; Liu Y; Lladó A; Lleó A; Nobili FM; Oguz KK; Parnetti L; Pereira J; Picco A; Pikkarainen M; de Oliveira CR; Saka E; Salvadori N; Sanchez-Valle R; Santana I; Scarpini E; Scheltens P; Soininen H; Tarducci R; Teunissen C; Tsolaki M; Urbani A; Vilaplana E; Visser PJ; Wallin AK; Yener G; Molinuevo JL; Meulenbroek O; Verbeek MM
    J Alzheimers Dis; 2017; 56(2):543-555. PubMed ID: 28059783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurodegenerative cerebrospinal fluid biomarkers tau and amyloid beta predict functional, quality of life, and neuropsychological outcomes after aneurysmal subarachnoid hemorrhage.
    Joswig H; Korte W; Früh S; Epprecht L; Hildebrandt G; Fournier JY; Stienen MN
    Neurosurg Rev; 2018 Apr; 41(2):605-614. PubMed ID: 28890998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.
    Liu C; Cholerton B; Shi M; Ginghina C; Cain KC; Auinger P; ; Zhang J
    Parkinsonism Relat Disord; 2015 Mar; 21(3):271-6. PubMed ID: 25596881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid biomarkers of neurodegeneration in patients with juvenile and classic myotonic dystrophy type 1.
    Peric S; Mandic-Stojmenovic G; Markovic I; Stefanova E; Ilic V; Parojcic A; Misirlic-Dencic S; Ostojic M; Rakocevic-Stojanovic V; Kostic V
    Eur J Neurol; 2014 Feb; 21(2):231-7. PubMed ID: 23834502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.
    Geijselaers SLC; Aalten P; Ramakers IHGB; De Deyn PP; Heijboer AC; Koek HL; OldeRikkert MGM; Papma JM; Reesink FE; Smits LL; Stehouwer CDA; Teunissen CE; Verhey FRJ; van der Flier WM; Biessels GJ;
    J Alzheimers Dis; 2018; 61(1):309-320. PubMed ID: 29154275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI.
    Wolfsgruber S; Jessen F; Koppara A; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Kornhuber J; Wagner M
    Neurology; 2015 Mar; 84(12):1261-8. PubMed ID: 25716354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
    Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
    BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interrelations between CSF soluble AβPPβ, amyloid-β 1-42, SORL1, and tau levels in Alzheimer's disease.
    Alexopoulos P; Guo LH; Tsolakidou A; Kratzer M; Grimmer T; Westerteicher C; Jiang M; Bujo H; Diehl-Schmid J; Kurz A; Perneczky R
    J Alzheimers Dis; 2012; 28(3):543-52. PubMed ID: 22045485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia.
    Oh ES; Blennow K; Bigelow GE; Inouye SK; Marcantonio ER; Neufeld KJ; Rosenberg PB; Troncoso JC; Wang NY; Zetterberg H; Sieber FE; Lyketsos CG
    PLoS One; 2018; 13(9):e0204695. PubMed ID: 30252906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.